Trial Watch: A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Later-Stage HumanInvestigationalNot addressed

Important context

Trial eligibility (participation has strict criteria): Clinical-trial participation has study-specific eligibility criteria; registry listing does not mean a person qualifies or should enroll.

What changed: ClinicalTrials.gov lists A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) (NCT06875310) as a Phase 3 interventional cancer study. The registry status is Recruiting, with the record last updated 2026-08-14.

Study snapshot: Phase 3; Recruiting; planned enrollment 630. Conditions listed: Carcinoma, Non-Small-Cell Lung. A primary outcome listed by the registry is: Progression Free Survival (PFS) as Assessed per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Blinded Independent Central Review (BICR).

This entry tracks verified trial-registry facts. Trial registration by itself does not show that an intervention is effective, safe for a particular person, FDA-approved for this use, or recommended by clinical guidelines.

What This Means

ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.

What This Doesn't Mean

A registered trial is not proof that the intervention works, is not FDA approval for this cancer or use, and is not a clinical-guideline recommendation.

Why It Matters

Phase 3 trials can contribute later-stage human evidence. CancerDiscoveries can track this record as results and regulatory information emerge.

Promise & Proof

Proof — strength of the evidence 4 / 5

Base score from evidence stage: Later-Stage Human.

Promise — potential significance if later evidence holds up 3 / 5

Baseline — a validly-evidenced story starts here; every further point below is an explicit, checkable reason.
The record includes substantive editorial reasoning about why this discovery matters.
Targets a cancer type with historically limited effective treatment options.

These two ratings are automatically computed from this story's own structured evidence fields and are shown separately on purpose — they are never combined into one score. They describe this record, not a medical recommendation: they do not establish medical certainty, do not substitute for reading the cited sources, and are recalculated whenever the underlying evidence changes.

Population / Applicability

Studied in: Participants age 18 Years and older with Carcinoma, Non-Small-Cell Lung who meet the study-specific registry eligibility criteria. (Adults)

Eligibility is study-specific. Registry information does not determine whether any individual should enroll in or receive the intervention.

Full evidence details

Study design: Other / not applicable
Sample size: 630
Primary outcome: Progression Free Survival (PFS) as Assessed per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Blinded Independent Central Review (BICR)
Replication: Unknown

Funding & Conflicts

ClinicalTrials.gov lists the lead sponsor as Mirati Therapeutics Inc.. Sponsorship is reported for transparency and does not establish efficacy.

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-08-14

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Guideline positions

Guideline

Position: Not addressed
Last verified: 2026-08-14

Primary evidence supporting this story

ClinicalTrials.gov — NCT06875310 (opens in a new tab) (Clinical-trial registry) NCT06875310 Load-bearing source NCT06875310
ClinicalTrials.gov — NCT06875310. NCT06875310.

Why Should I Trust This?

1 source at Tier 1 — Government/regulatory authority (FDA, NCI, NIH, ClinicalTrials.gov, CDC, and equivalent)
Correction/retraction status: No correction or retraction
Last reviewed: 2026-08-14

This panel summarizes real, checkable facts about this record's own sources and review status — it is not a trust score, and reading it is not a substitute for reading the cited sources yourself.

Discovery Timeline

Every recorded change to this record's content or publication status, in order.

2026-08-14 Status change — Status changed from "In editorial review" to "Verified".
2026-08-14 Status change — Status changed from "Legacy / Unverified" to "In editorial review".

Last reviewed 2026-08-14